Key result
Abciximab during primary PCI linked to profound thrombocytopenia of 3000/μL managed with platelet transfusions.
Why the study?
Acute profound thrombocytopenia is a rare complication of abciximab used during PCI for acute coronary syndrome patients.
Case Report (n=1)
No
Highlights the successful management of acute profound thrombocytopenia, a rare complication of abciximab use during primary PCI for STEMI.
Supports vigilance for abciximab-induced thrombocytopenia in PCI; hypothesis-generating and should not change practice.
Glycoprotein IIb/IIIa antagonists are well established for their effectiveness in improving clinical outcomes in acute coronary syndrome patients undergoing percutaneous coronary intervention. Acute profound thrombocytopenia is a rare complication of abciximab. We present a case which was managed successfully for the rare complication of acute profound thrombocytopenia after using abciximab and an intra-aortic balloon pump for the treatment of a no-reflow phenomenon and consecutive cardiogenic shock during primary percutaneous coronary intervention.
No takes yet. Share an insight, caveat, or question.
Park et al. (2013) conducted a case report in ST-Segment Elevation Myocardial Infarction (STEMI) and no-reflow phenomenon (n=1). Abciximab was evaluated on Platelet count. Administration of abciximab for no-reflow phenomenon during primary PCI resulted in acute profound thrombocytopenia (platelet count 3000/μL), which was successfully managed with platelet transfusions.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: